POSaBIT cannabis payments infrastructure just got cheaper to finance. The company has refinanced its $4.75 million loan with Perga Capital Partners LP. It will repay $2 million of principal over the next 18 months, push maturity from March 2028 to March 2030, and cut the interest rate from 12% to 10% immediately, with a further step down to 9% starting January 1, 2027.

Inside the POSaBIT cannabis payments refinancing

Read the structure carefully, because it is not a clean two-year reprieve. After March 31, 2028, the remaining balance amortises through monthly principal and interest payments over the 24 months to March 31, 2030. So repayment pressure resumes in April 2028. What moves out is the final maturity, not the start of the grind.

One more detail sits in the fine print. The size of the third prepayment depends on POSaBIT receiving a tax refund. That is a thinner read on POSaBIT cannabis payments cash flow than a straight paydown would be.

Fintechbits analysis

Why POSaBIT cannabis payments lending is a small pool

This is a small deal by fintech standards. Still, it says something about where the company sits. Since launch, POSaBIT has spent years building payment processing, ATM and point-of-sale systems for an industry mainstream banks mostly will not touch. That gap is the entire business model.

However the lender detail deserves more scepticism than a press release invites. Perga is a related party, and it subscribed for shares in a POSaBIT placement back in 2023. So this is not an arm’s-length lender choosing to stick around. It is an insider with equity exposure restructuring its own position, which is a different signal entirely.

Two extra years and a lower rate still matter more for a company this size than for a larger processor. Every basis point saved on a $4.75 million facility drops straight to the bottom line, and the cost of capital is the binding constraint here.

What POSaBIT cannabis payments still cannot fix

None of this means cannabis payments got easier. Meanwhile something big did change this year, and it changed nothing that matters to POSaBIT.

In April 2026 the DEA moved two categories of marijuana from Schedule I to Schedule III. Those are marijuana in FDA-approved drug products and marijuana under a qualifying state medical licence. Adult-use and bulk marijuana stayed in Schedule I. An expedited hearing on broader rescheduling ran through mid-July, with a decision still pending.

Yet rescheduling did not touch the plumbing. Bank Secrecy Act and anti-money-laundering obligations still apply, and FinCEN has not updated its cannabis banking guidance. More to the point for a payments company, Visa and Mastercard still prohibit cannabis transactions at the network level, and neither announced any change after April.

So the workarounds stay: closed-loop systems, state-chartered bank relationships, and the rest of the architecture POSaBIT cannabis payments rivals have built around a blocked front door. POSaBIT trades over the counter and on the Canadian Securities Exchange rather than a major US exchange, itself a symptom of how federal law boxes these companies out of the largest capital markets.

In sum, a refinancing with better terms is a real, if modest, win. It is not evidence the regulatory problem is going away. Indeed the past year is the strongest proof yet that it is not, because the industry got its biggest federal shift in decades and the card networks did not blink.

What to watch next for POSaBIT cannabis payments

Watch whether POSaBIT uses the freed-up cash flow to expand into new state markets or simply to stabilise the balance sheet. April 2028 is the date that matters, since amortisation starts then rather than 2030.

Above all, watch the two things that would truly change POSaBIT cannabis payments economics. First, whether the pending broader rescheduling decision reaches adult-use cannabis. Second, whether the long-stalled SAFE Banking Act moves at all before this loan comes due again.

Fintechbits covers payments infrastructure, regulated-industry fintech, and cannabis banking. Nothing here constitutes financial or investment advice. All analysis represents the editorial views of Fintechbits.